01—Abstract
Summary
Summary of the 8-K filed October 1, 2025. Cited figures are marked; the original filing is the authoritative source.
On September 29, 2025, Honeywell permanently divested its legacy Bendix asbestos liabilities and certain non-Bendix asbestos liabilities by selling Sterling Wander LLLP, an indirect subsidiary, to Delticus, a corporate liability acquisition platform.
Sterling Wander was capitalized with the related insurance assets and approximately $1.68 billiona in cash. Honeywell reports that a solvency opinion from an independent advisory firm supported the conclusion that Sterling Wander and its subsidiaries were solvent and adequately capitalized at closing. Delticus now manages the claims and insurance reimbursements, and the liabilities and related insurance assets will be removed from Honeywell's consolidated balance sheet.
For investors, the key financial points are a one-time after-tax loss of approximately $115 millionb, which the company will exclude from Adjusted EPS, and an expected improvement of more than $100 million in annual free cash flow over the next several years, with that benefit declining over time. Honeywell states it will have no further financial exposure to the transferred liabilities and is fully indemnified. The company funded part of its contribution using a portion of the approximately $1.6 billion in cash received from the recently announced Resideo Indemnification and Reimbursement Agreement termination.
The filing does not disclose Honeywell's exact share of the $1.68 billionc versus Delticus's share. The transaction is framed as part of Honeywell's broader portfolio simplification ahead of its planned separation into three independent companies, which the company expected to complete in the second half of 2026.
The 8-K also references the proposed spin-off of Advanced Materials into Solstice Advanced Materials, the proposed separation of Automation and Aerospace Technologies, and the evaluation of strategic alternatives for the Productivity Solutions and Services and Warehouse and Workflow Solutions businesses. These items are forward-looking and subject to risks, and the filing notes that plans may be modified or abandoned.
02—Key points
Key Highlights
- Honeywell permanently divested all Bendix asbestos liabilities and certain non-Bendix asbestos liabilities to Delticus via the sale of Sterling Wander LLLP, closed September 29, 2025.
- Approximately $1.68 billion in cash and related insurance assets were contributed to Sterling Wander, with Delticus assuming full responsibility for administering and resolving current and future asbestos claims.
- Honeywell expects a one-time after-tax loss of approximately $115 million, which will be excluded from Adjusted EPS.
- The transaction is expected to improve annual free cash flow by more than $100 million over the next several years, with the benefit decreasing over time.
- Honeywell reports no further financial exposure to the transferred liabilities and states it is fully indemnified.
- The transaction was partly funded with cash from the approximately $1.6 billion Resideo Indemnification and Reimbursement Agreement termination.
- The divestiture supports portfolio simplification ahead of the planned three-way separation, which was expected to complete in the second half of 2026.
03—Questions
Frequently Asked Questions
What exactly did Honeywell sell, and to whom?
Honeywell sold Sterling Wander LLLP, an indirect subsidiary holding its legacy Bendix asbestos liabilities, certain non-Bendix asbestos liabilities, and the related insurance assets, to Delticus, a corporate liability acquisition platform. Delticus now manages Sterling Wander and its subsidiaries, including claims handling and insurance reimbursements.
What is the financial impact on Honeywell's earnings and cash flow?
Honeywell expects a one-time after-tax loss of about $115 million, which it will exclude from Adjusted EPS. The company expects the transaction to improve annual free cash flow by more than $100 million over the next several years, with that benefit declining over time.
Does Honeywell retain any risk from these asbestos liabilities?
According to the company, Honeywell will have no further financial exposure to the transferred liabilities and is fully indemnified. The solvency opinion supported the determination that Sterling Wander and its subsidiaries were solvent and adequately capitalized at closing. Investors should note that this relies on the company's own characterization and the terms of the indemnification, which are not detailed in the filing.
How was the transaction funded?
Sterling Wander was capitalized with approximately $1.68 billion in cash along with the related insurance assets. Honeywell used a portion of the roughly $1.6 billion received from the Resideo Indemnification and Reimbursement Agreement termination to fund its contribution. The filing does not break out how much of the $1.68 billion came from Honeywell versus Delticus.
How does this fit into Honeywell's broader strategy?
The company describes the divestiture as part of its effort to simplify its portfolio and redeploy capital toward core growth priorities, ahead of its planned separation into three independent companies. The same filing references the proposed Advanced Materials spin-off into Solstice Advanced Materials, the proposed separation of Automation and Aerospace Technologies, and a review of strategic alternatives for Productivity Solutions and Services and Warehouse and Workflow Solutions. These plans are forward-looking, not final, and could be modified or abandoned.
04—Continue